
Nuvation Bio Inc.: updates and filings
Price
$3.78
November 18, 2026Market cap $1.3B
What Ploutos Investor adds for Nuvation Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 20% since Nov 4, 2026, when the 10-Q these figures come from was filed ($4.73 then, $3.78 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Results of operationsForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 6, 2026New material financial obligation, other material eventsForm8-K
- Jun 30, 2026Material agreement entered, material agreement ended, new material financial obligation, other material eventsForm8-K
- Jun 29, 2026FilingForm305B2
- May 27, 2026Shareholder voteForm8-K
- May 4, 2026Results of operationsForm8-K
- May 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 10, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 10, 2026Annual meeting proxy statementFormDEF 14A
- Mar 3, 2026Shares registered for employeesFormS-8
- Mar 2, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 2, 2026Results of operationsForm8-K
- Feb 10, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Jan 12, 2026Material agreement entered, results of operations, Regulation FD disclosureForm8-K
- Nov 26, 2025Regulation FD disclosure, other material eventsForm8-K
- Nov 17, 2025Regulation FD disclosure, other material eventsForm8-K
- Nov 3, 2025Shares registered for employeesFormS-8
- Nov 3, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 3, 2025Results of operationsForm8-K
- Aug 7, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Aug 7, 2025Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 6, 2026 | 8-K | New material financial obligation, other material events | Document |
| Jun 30, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation, other material events | Document |
| Jun 29, 2026 | 305B2 | Filing | Document |
| May 27, 2026 | 8-K | Shareholder vote | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| May 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 10, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 10, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 3, 2026 | S-8 | Shares registered for employees | Document |
| Mar 2, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 2, 2026 | 8-K | Results of operations | Document |
| Feb 10, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Jan 12, 2026 | 8-K | Material agreement entered, results of operations, Regulation FD disclosure | Document |
| Nov 26, 2025 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 17, 2025 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 3, 2025 | S-8 | Shares registered for employees | Document |
| Nov 3, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 3, 2025 | 8-K | Results of operations | Document |
| Aug 7, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Aug 7, 2025 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 15, 2020.
The full analysis
What do Nuvation Bio's filings show?
The filings are where every one of Nuvation Bio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.